Acp-103
Parkinson Disease Psychosis
Humanis Saglık Anonim SirketiPhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 55/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the Parkinson Disease Psychosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ulotaront Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 2 | B |
agb101 Johns Hopkins University | Phase 2 | CCC |
Iloperidone Vanda Pharmaceuticals | Phase 2 | CCC |
fb418 1ST Biotherapeutics, Inc. | Phase 1 | CC |
ly03017 Luye Pharma Group Ltd. | Phase 1 | CC |
azd0530 King's College London | Early Phase 1 | C |
Same molecule, other indications
Acp-103 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →